first_imgTua Tagovailoa points directions to a teammate.TUSCALOOSA, AL – SEPTEMBER 08: Tua Tagovailoa #13 of the Alabama Crimson Tide runs the offense against the Arkansas State Red Wolves at Bryant-Denny Stadium on September 8, 2018 in Tuscaloosa, Alabama. (Photo by Kevin C. Cox/Getty Images)A caller into The Paul Finebaum Show on ESPN made a despicable comment about Alabama quarterback Tua Tagovailoa heading into next weekend’s game against LSU.The caller, Darriel from Columbus, had a suggestion for how the Tigers can beat the seemingly unbeatable Crimson Tide.“The way you beat Alabama is you take out Tua’s knee,” Darriel said, per 247Sports. “Who cares about a head shot? Take out a knee and you got them beat. They still haven’t beaten nobody. I’m glad they’re disrespecting LSU like this. When they knock Tua out and LSU wins and Alabama struggles to beat Mississippi State and then loses to Auburn, it’s over. It is o-v-e-r. That’s the way it’s going to play out, you watch.“The fall is going to be hard and I’m going to love every second of it.”Tua has been dealing with a knee injury this season. He missed part of a game earlier this season after suffering a scary sprain on the field.Finebaum, unsurprisingly, was not happy with the suggestion.“You know me, Darriel, I don’t preach,” Finebaum said. “Anyone that would call into this program or put on Twitter a suggestion in doing serious injury to a college football player is disgusting. It may be legal, but it’s despicable. I can’t believe you would even write that down.”Alabama and LSU are set to meet in Baton Rouge, La. on Saturday, Nov. 3. Kickoff is set for 8 p.m. E.T. on CBS.last_img read more

Valeant CEO on medical leave with pneumonia, company says by The Canadian Press Posted Dec 28, 2015 8:09 am MDT Last Updated Dec 28, 2015 at 8:40 am MDT AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email LAVAL, Que. – Embattled pharmaceutical firm Valeant International says its chief executive is taking a medical leave of absence.The Quebec-based company previously revealed that Michael Pearson was hospitalized last week with what it described as a severe case of pneumonia.Valeant (TSX:VRX) did not offer updates on Pearson’s condition, but says his leave of absence takes effect immediately.Valeant says Pearson’s duties will be shared on an interim basis between General Council Robert Chai-Onn, Company Group Chairman Ari Kellen, and Chief Financial Officer Robert Rosiello.Valeant has been facing a series of scandals that have slashed its stock price by more than half since record highs posted in August.The company is facing a congressional investigation in the U.S. over its pricing practices and has been forced to revise its 2016 outlook after ending a drug distribution agreement with the controversial Philidor mail-order pharmacy.Pearson himself had been facing criticism for Valeant’s share price collapse and recently struck a defiant tone after calls for his dismissal surfaced.“If the board wants to fire me they are welcome to fire me, but until they do we’re going to get through this thing,” Pearson told investors during a Dec. 16 webcast.Valeant said the October split from specialty pharmaceutical partner Philidor Rx Services caused a big short-term disruption to its business that would reduce its expectations for the fourth quarter and 2015 as a whole.But Pearson had also indicated that a new distribution agreement with major U.S. drug store chain Walgreens had set the company back on the road to recovery.Pearson, 56, joined Valeant in 2008 after a 23-year career with the consulting firm McKinsey & Co., for which he served as head of its global pharmaceutical practice.He used a string of acquisitions to turn a relatively small business that made generic drugs and chronic illness treatments into a major pharmaceutical company. Valeant, formerly based in California, combined with Wellbutrin XL maker Biovail in 2010 to form Laval, Quebec-based Valeant Pharmaceuticals International Inc. Its sales climbed from US$2.46 billion in 2011 to an expected US$10.4 billion to US$10.5 billion for this year.Valeant shares closed at $157.68 on Thursday, the most recent day on which the Toronto Stock Exchange was open for trading.That figure was well up from a 52-week low of $92.65 but well shy of a historic high of $347.84 in August.— With Files from the Associated Press read more